1579251-94-7 Usage
Description
(R)-4-(2-chloro-4-fluoro-phenyl)-6-methyl-2-thiazol-2-yl-1,4-dihydro-pyrimidine-5-carboxylic acid methyl ester is a complex organic molecule with a pyrimidine core, featuring an ester group, a thiazole ring, a fluorophenyl group, and a methyl and chloro substituent. This derivative of pyrimidine and thiazole is recognized for its potent inhibitory effects on specific enzymes, which may contribute to its potential applications in pharmaceutical research and drug development due to its unique structure and biological activities.
Uses
Used in Pharmaceutical Research:
(R)-4-(2-chloro-4-fluoro-phenyl)-6-methyl-2-thiazol-2-yl-1,4-dihydro-pyrimidine-5-carboxylic acid methyl ester is used as a research compound for its potential to inhibit specific enzymes, which can be crucial in understanding various biological pathways and developing targeted therapies.
Used in Drug Development:
In the pharmaceutical industry, (R)-4-(2-chloro-4-fluoro-phenyl)-6-methyl-2-thiazol-2-yl-1,4-dihydro-pyrimidine-5-carboxylic acid methyl ester is used as a lead compound in the development of new drugs. Its potent enzyme-inhibiting properties make it a promising candidate for creating medications that could treat a range of diseases by targeting the underlying biochemical processes.
Used in Enzyme Inhibition Studies:
(R)-4-(2-chloro-4-fluoro-phenyl)-6-methyl-2-thiazol-2-yl-1,4-dihydro-pyrimidine-5-carboxylic acid methyl ester is utilized as a tool in enzyme inhibition studies to investigate the interactions between the compound and its target enzyme. This can provide valuable insights into the enzyme's function and the potential therapeutic applications of the molecule.
Used in Chemical Synthesis:
(R)-4-(2-chloro-4-fluoro-phenyl)-6-methyl-2-thiazol-2-yl-1,4-dihydro-pyrimidine-5-carboxylic acid methyl ester is also used as a synthetic building block in the creation of more complex molecules with potential applications in various fields, including materials science and medicinal chemistry, due to its diverse functional groups and structural features.
Check Digit Verification of cas no
The CAS Registry Mumber 1579251-94-7 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,5,7,9,2,5 and 1 respectively; the second part has 2 digits, 9 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 1579251-94:
(9*1)+(8*5)+(7*7)+(6*9)+(5*2)+(4*5)+(3*1)+(2*9)+(1*4)=207
207 % 10 = 7
So 1579251-94-7 is a valid CAS Registry Number.
1579251-94-7Relevant articles and documents
DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES
-
Page/Page column 65-66, (2021/02/05)
Provided are dihydropyrimidine derivatives which are useful in the treatment or prevention of HBV infection or of HBV-induced diseases, more particularly of HBV chronic infection or of diseases induced by HBV chronic infection, as well as pharmaceutical or medical applications thereof.
HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS
-
Page/Page column 45; 51; 52, (2020/07/14)
Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.
3-((R)-4-(((R)-6-(2-Bromo-4-fluorophenyl)-5-(ethoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)morpholin-2-yl)propanoic Acid (HEC72702), a Novel Hepatitis B Virus Capsid Inhibitor Based on Clinical Candidate GLS4
Ren, Qingyun,Liu, Xinchang,Yan, Guanghua,Nie, Biao,Zou, Zhifu,Li, Jing,Chen, Yunfu,Wei, Yu,Huang, Jianzhou,Luo, Zhonghua,Gu, Baohua,Goldmann, Siegfried,Zhang, Jiancun,Zhang, Yingjun
, p. 1355 - 1374 (2018/02/17)
The inhibition of hepatitis B virus (HBV) capsid assembly is a novel strategy for the development of chronic hepatitis B (CHB) therapeutics. On the basis of the preclinical properties and clinical results of GLS4, we carried out further investigation to seek a better candidate compound with appropriate anti-HBV potency, reduced hERG activity, decreased CYP enzyme induction, and improved pharmacokinetic (PK) properties. To this end, we have successfully found that morpholine carboxyl analogues with comparable anti-HBV activities to that of GLS4 showed decreased hERG activities, but they displayed strong CYP3A4 induction in a concentration-dependent manner, except for morpholine propionic acid analogues. After several rounds of modification, compound 58 (HEC72702), which had an (R)-morpholine-2-propionic acid at the C6 position of its dihydropyrimidine core ring, was found to display no induction of the CYP1A2, CYP3A4, or CYP2B6 enzyme at the high concentration of 10 μM. In particular, it demonstrated a good systemic exposure and high oral bioavailability and achieved a viral-load reduction greater than 2 log in a hydrodynamic-injected (HDI) HBV mouse model and has now been selected for further development.
